Walk in or schedule your Pfizer COVID-19 vaccine! Monday through Thursday: 8 a.m. - 5 p.m. and Friday: 8 a.m. - noon >

Eric H. Bernicker VIEW CLINICAL PROFILE

Eric H. Bernicker, MD

Professor of Clinical Oncology, Academic Institute
Full Clinical Member, Research Institute
Diane Harkins Modesett Clinical Academic Scholar, Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of SWOG trials, and industry trials of novel targeted agents. 

Description of Research

Dr. Bernicker’s research focuses on looking at different therapeutic approaches, such as targeted therapies and immunotherapies, in the treatment of lung cancer. By understanding how to identify patients at risk for relapse after surgery or those who can be spared the toxicities of chemotherapy, the immune system can be stimulated to preferentially destroy tumor cells, spare normal tissues, and improve patient survival along with the development of less toxic therapeutics. Eventually, the goal is to be able to offer new therapies and clinical trials to patients at Methodist with any stage of non-small cell lung cancer or small cell lung cancer.

Areas Of Expertise

Lung cancer Cancer research Targeted therapeutics
Education & Training

MD, Baylor College of Medicine
Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
Internship, Dallas County Hospital -Parkland Memorial Hospital
Active Clinical Trials

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

NCT02193282


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT02201992


A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

NCT03070392


A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

NCT03132675


A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)

NCT03968419


View All
Publications

Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis
Chevli, N, Hunt, A, Haque, W, Farach, AM, Messer, JA, Sukpraprut-Braaten, S, Bernicker, EH, Zhang, J, Butler, EB & Teh, BS 2021, , Advances in Radiation Oncology, vol. 6, no. 6, 100783. https://doi.org/10.1016/j.adro.2021.100783

Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: A single institution experience
Burns, EA, Ensor, JE, Hsu, J, Thomas, JS, Olsen, RJ & Bernicker, EH 2021, , Journal of Thoracic Disease, vol. 13, no. 8, pp. 4785-4796. https://doi.org/10.21037/jtd-21-432

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Grivas, P, Khaki, AR, Wise-Draper, TM, French, B, Hennessy, C, Hsu, CY, Shyr, Y, Li, X, Choueiri, TK, Painter, CA, Peters, S, Rini, BI, Thompson, MA, Mishra, S, Rivera, DR, Acoba, JD, Abidi, MZ, Bakouny, Z, Bashir, B, Bekaii-Saab, T, Berg, S, Bernicker, EH, Bilen, MA, Bindal, P, Bishnoi, R, Bouganim, N, Bowles, DW, Cabal, A, Caimi, PF, Chism, DD, Crowell, J, Curran, C, Desai, A, Dixon, B, Doroshow, DB, Durbin, EB, Elkrief, A, Farmakiotis, D, Fazio, A, Fecher, LA, Flora, DB, Friese, CR, Fu, J, Gadgeel, SM, Galsky, MD, Gill, DM, Glover, MJ, Goyal, S, Grover, P, Gulati, S, Gupta, S, Halabi, S, Halfdanarson, TR, Halmos, B, Hausrath, DJ, Hawley, JE, Hsu, E, Huynh-Le, M, Hwang, C, Jani, C, Jayaraj, A, Johnson, DB, Kasi, A, Khan, H, Koshkin, VS, Kuderer, NM, Kwon, DH, Lammers, PE, Li, A, Loaiza-Bonilla, A, Low, CA, Lustberg, MB, Lyman, GH, McKay, RR, McNair, C, Menon, H, Mesa, RA, Mico, V, Mundt, D, Nagaraj, G, Nakasone, ES, Nakayama, J, Nizam, A, Nock, NL, Park, C, Patel, JM, Patel, KG, Peddi, P, Pennell, NA, Piper-Vallillo, AJ, Puc, M, Ravindranathan, D, Reeves, ME, Reuben, DY, Rosenstein, L, Rosovsky, RP, Rubinstein, SM, Salazar, M, Schmidt, AL, Schwartz, GK, Shah, MR, Shah, SA, Shah, C, Shaya, JA, Singh, SRK, Smits, M, Stockerl-Goldstein, KE, Stover, DG, Streckfuss, M, Subbiah, S, Tachiki, L, Tadesse, E, Thakkar, A, Tucker, MD, Verma, AK, Vinh, DC, Weiss, M, Wu, JT, Wulff-Burchfield, E, Xie, Z, Yu, PP, Zhang, T, Zhou, AY, Zhu, H, Zubiri, L, Shah, DP, Warner, JL & Lopes, GL 2021, , Annals of Oncology, vol. 32, no. 6, pp. 787-800. https://doi.org/10.1016/j.annonc.2021.02.024

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
Li, J, Zhang, B, Zhang, Y, Xu, F, Zhang, Z, Shao, L, Yan, C, Ulivi, P, Denis, MG, Christopoulos, P, de Montpréville, VT, Bernicker, EH, van der Wekken, AJ, Wang, C & Yue, D 2021, , Translational Lung Cancer Research, vol. 10, no. 3, pp. 1525-1535. https://doi.org/10.21037/tlcr-21-160

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers
Bernicker, EH, Xiao, Y, Abraham, A, Yang, B, Croix, DA, Redpath, S, Engstrom-Melnyk, J, Shah, R, Madala, J & Allen, TC 2021, , Oncologist, vol. 26, no. 6, pp. e1050-e1057. https://doi.org/10.1002/onco.13779

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
The COVID-19 and Cancer Consortium 2020, , Cancer Cell, vol. 38, no. 6, pp. 761-766. https://doi.org/10.1016/j.ccell.2020.10.022

Understanding the associations between smoking-related risk perception, interest in quitting smoking, and interest in lung cancer screening among homeless adult smokers
Agrawal, P, Taing, M, Chen, TA, Reuven, SM, Businelle, MS, Kendzor, DE, Bernicker, EH & Reitzel, LR 2020, , International journal of environmental research and public health, vol. 17, no. 23, 8817, pp. 1-11. https://doi.org/10.3390/ijerph17238817

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma
Anand, K, Phung, TL, Bernicker, EH, Cagle, PT, Olsen, RJ & Thomas, JS 2020, , Clinical Lung Cancer, vol. 21, no. 5, pp. 437-442. https://doi.org/10.1016/j.cllc.2020.05.007

Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database
Messer, JA, Zuhour, RJ, Haque, W, Lewis, GD, Schefler, AC, Wong, A, Bernicker, EH, Chevez-Barrios, P, Michelle Quan, E, Farach, A, Butler, EB, Hatch, SS & Teh, BS 2020, , Journal of Contemporary Brachytherapy, vol. 12, no. 4, pp. 303-310. https://doi.org/10.5114/jcb.2020.98108

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
COVID-19 and Cancer Consortium 2020, , The Lancet, vol. 395, no. 10241, pp. 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
Kasparian, S, Gentille, C, Burns, E & Bernicker, EH 2020, , JTO Clinical and Research Reports, vol. 1, no. 2, 100017. https://doi.org/10.1016/j.jtocrr.2020.100017

Cancer cachexia: A multifactoral disease that needs a multimodal approach
Stubbins, R, Bernicker, EH & Quigley, EM 2020, , Current opinion in gastroenterology, vol. 36, no. 2, pp. 141-146. https://doi.org/10.1097/MOG.0000000000000603

Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant
L Hefler, J, M Bailey, L, El Rahi, C, C Schefler, A & Bernicker, EH 2021, , Journal of Oncology Pharmacy Practice, vol. 27, no. 5, pp. 1261-1264. https://doi.org/10.1177/1078155220969792

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
Anand, K, Ensor, J, Trachtenberg, B & Bernicker, EH 2019, , JACC: CardioOncology, vol. 1, no. 2, pp. 172-178. https://doi.org/10.1016/j.jaccao.2019.10.006

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
Chitturi, KR, Xu, J, Araujo-Gutierrez, R, Bhimaraj, A, Guha, A, Hussain, I, Kassi, M, Bernicker, EH & Trachtenberg, BH 2019, , JACC: CardioOncology, vol. 1, no. 2, pp. 182-192. https://doi.org/10.1016/j.jaccao.2019.11.013

A matter of comprehensive informed consent: Short-term mortality rates with definitive treatment options in elderly stage i NSCLC
Dalwadi, SM, Savjani, RR, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2019, , American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 42, no. 11, pp. 851-855. https://doi.org/10.1097/COC.0000000000000606

Socioeconomic Factors Associated with Lack of Treatment in Early Stage Non-Small Cell Lung Cancer
Dalwadi, SM, Zhang, J, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2019, , Cancer Investigation, vol. 37, no. 9, pp. 506-511. https://doi.org/10.1080/07357907.2019.1666136

The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients — the Benefits of Diversity
Bernicker, EH & Quigley, EMM 2019, , Journal of Thoracic Oncology, vol. 14, no. 8, pp. 1319-1322. https://doi.org/10.1016/j.jtho.2019.05.016

Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma
Schefler, AC, Koca, E, Bernicker, EH & Correa, ZM 2019, , Graefes Archive for Clinical and Experimental Ophthalmology, vol. 257, no. 7, pp. 1541-1545. https://doi.org/10.1007/s00417-019-04335-w

Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century
Dalwadi, SM, Lewis, GD, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2019, , Clinical Lung Cancer, vol. 20, no. 3, pp. 194-200. https://doi.org/10.1016/j.cllc.2018.11.004

VIEW FULL PUBLICATIONS